Citation | Devasthale, P; Wang, Y; Wang, W; Fevig, J; Feng, J; Wang, A; Harrity, T; Egan, D; Morgan, N; Cap, M; Fura, A; Klei, HE; Kish, K; Weigelt, C; Sun, L; Levesque, P; Moulin, F; Li, YX; Zahler, R; Kirby, MS; Hamann, LG Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778). J Med Chem56:7343-57 (2013) [PubMed] Article |
---|
SMILES | CCCN(C)C(=O)Cn1cc2[nH]c(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2c1=O |(5.49,-27.06,;6.26,-28.39,;5.5,-29.73,;6.28,-31.06,;7.82,-31.05,;5.51,-32.4,;3.97,-32.41,;6.29,-33.73,;7.83,-33.72,;8.73,-32.46,;10.21,-32.94,;11.54,-32.17,;12.87,-32.93,;14.2,-32.16,;12.88,-34.48,;14.21,-35.25,;15.55,-34.48,;11.55,-35.25,;11.54,-36.79,;10.21,-37.55,;10.2,-39.09,;11.53,-39.87,;11.53,-41.41,;12.87,-39.09,;12.87,-37.56,;14.2,-36.79,;10.22,-34.48,;8.75,-34.97,;8.28,-36.44,)| |